CA-SCIENTIST.COM
1.4.2021 13:57:06 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading marketplace for life science research, announced today that it has partnered with Charles River , Certis Oncology and other leading oncology CROs to launch a Disease Model Finder that helps medical researchers use genetic, cellular and patient data to find the most appropriate research models for their preclinical development projects.
“Our proprietary model selection software uses multiple machine learning algorithms to help researchers sift through large amounts of data and identify in vitro and in vivo models for their research,” stated Javier Pineda, PhD, Data Scientist at Scientist.com. “Scientists can filter by gene mutation, gene expression, cancer type or patient information, and then purchase without delay once the right model is identified.”
The Disease Model Finder brings together a wealth of data that can help scientists choose the right preclinical disease models. DNA sequencing data from CRO partners is uploaded and analyzed so that researchers can easily search for models based on the presence (or absence) of a mutated gene or by the up or down regulation of gene expression. Marketplace customers can then filter their search results based on cancer type, subtype and characteristics or patient information.
“Scientist.com’s new Disease Model Finder will enable pharma and biotech researchers to find and purchase the most appropriate Charles River models for their drug development programs,” said Melissa Schroeder, E-Commerce Manager at Charles River. “Having access to advanced data that better matches a patient-derived xenograft (PDX) model with a research program will enable optimal study design, ultimately saving time and money as clients race to get critical therapies to patients.”
At launch, the Disease Model Finder includes 650 PDX models provided by Charles River, Certis, XenTech , the Lab for Innovated Diagnosis and Experimental Therapeutics (LIDE) and others—a number that is projected to grow quickly as more CROs join the program. By 2022, the platform will include other model systems including organoids, cell-derived xenografts (CDX), syngeneic models, immunoncology models and patient-derived cell lines.
“With so many drugs failing in human clinical trials because they don’t work, it is imperative that we use more predictive preclinical models of disease,” stated Peter Ellman, Certis Oncology CEO. “By combining gene analysis, patient data and tissue profiling data, Scientist.com’s Disease Model Finder increases the odds that researchers are selecting the right Certis models for translational drug development.”
To learn more please visit https://www.scientist.com/disease-model-finder/
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay Releases 2026 Sustainability Report Highlighting Transformative Progress Across Social, Economic, and Environmental Impact Globally30.7.2026 14:03:00 CEST | Press release
Beauty Leader Ranked #8 on Forbes’ 2026 Best Brands For Social Impact List Mary Kay Inc., a leading global beauty company committed to sustainability and women’s empowerment, today released its 2026 Sustainability Report, outlining progress toward its 2030 goals and celebrating the 2025 and latest achievements that continue to drive positive change globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730240667/en/ Mary Kay's annual 2026 Sustainability Report highlights the company's decades-long dedication to social, economic, and environmental sustainability - core pillars central to its business strategy and its purpose-driven legacy rooted in Mary Kay's mission of “enriching women’s lives” around the world. (Image Credit: Mary Kay Inc.) The annual report highlights Mary Kay’s decades-long dedication to social, economic, and environmental sustainability - core pillars central to its business strategy and its purpose
INNIO Awarded EcoVadis Platinum Medal for Fifth Consecutive Year30.7.2026 14:00:00 CEST | Press release
INNIO N.V. (Nasdaq: INIO) has been awarded the EcoVadis Platinum Medal, the highest recognition granted by the globally trusted provider of business sustainability ratings. This marks the fifth consecutive year that INNIO has achieved Platinum status since 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730309718/en/ INNIO N.V. Awarded EcoVadis Platinum Medal for Fifth Consecutive Year In the latest assessment cycle, INNIO further improved its overall EcoVadis score compared to the previous year by introducing additional policies and further strengthening its sustainability management system. “This recognition is a strong validation of our sustainability strategy,” said Marcin Kawa, Vice President Sustainability at INNIO. “Achieving EcoVadis Platinum status for the fifth consecutive year shows that we have consistently delivered on our sustainability commitments and embedded responsible business practices throughout
Veracode Launches “Veracode Marketplace”: A Curated Ecosystem of Elite Security Integrations Built for the AI-Powered Software Development Era30.7.2026 14:00:00 CEST | Press release
DryRun Security Joins as Inaugural Partner, Extending Application Security to Code Intent, Business Logic, and AI-Generated Software Veracode, the global leader in application risk management, today announced the launch of the Veracode Marketplace, a curated ecosystem that gives customers a single, trusted destination to discover, evaluate, and deploy third-party security integrations as an extension of the Veracode platform. The marketplace debuts with DryRun Security as its inaugural partner, delivering AI-native contextual analysis and verification to Veracode customers on day one. A New Standard for the AppSec Ecosystem The Veracode Marketplace enables security and engineering teams to extend their existing Veracode investment with validated, best-in-class integrations. Every partner is vetted for technical depth, product quality, and workflow fit. Integrations are anchored to Veracode findings for a unified audit trail, and every purchase goes through a single procurement path on
Reply S.p.A: The Board of Directors Approves theHalf-year Financial Reportas of 30 June 202630.7.2026 13:52:00 CEST | Press release
All economic and financial indicators grew:Consolidated turnover of €1,311.9 million (1,221.3 in H1 2025);EBITDA of €233.2 million (223.7 in H1 2025);EBIT a of €189.7 million (188.4 in H1 2025);Pre-tax profit of €194.1 million (179.4 in H1 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 30 June 2026. Since the start of the year, the Group has recorded a consolidated turnover of €1,311.9 million which is an increase of 7.4% compared to the same period in 2025. All indicators are positive for the period. In the first half of 2026 consolidated EBITDA of €233.2 million compared to the €223.7 million recorded in 2025 and corresponds to 17.8% of turnover. EBIT, from January to June, was €189.7 million (€188.4 million in 2025), corresponding to 14.5% of turnover. Pre-tax profit, from January to June 2026, was €194.1 million (€179.4 million in 2025), corresponding to 14.8% of turnover. As regards the second quarter of 2026, the Group's performan
De' Longhi Group: a Quarter of Robust Revenue Growth of 8.4% and Solid Margin Expansion Drives an Upward Guidance Revision30.7.2026 13:47:00 CEST | Press release
Substantial expansion in Professional and acceleration in Household drive growth and margins, enabling further investments in marketing and product innovation as part of the Group's continuous strategic evolution The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the first half of 2026: In the first half the Group achieved: revenues for € 1,676.3 million, up by 5.8% with respect to last year (+8.0% at constant currency); an adjusted2 Ebitda of € 283.7 million, equal to 16.9% on revenues (vs. 15.2% in H1-25); a net income pertaining to the Group equal to € 141.4 million (+21.2% with respect to last year); a positive net financial position equal to € 686.6 million. CEO Fabio de' Longhi commented: “The solid results for the first half of 2026 provide the ideal backdrop to celebrate our first twenty-five years as a listed company. This milestone marks a transformative journey in which, thanks to the commitment and passion of our people, we have consistently
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom